CPHI Americas

Lilly Agrees to Acquire SiteOne Therapeutics

The transaction includes STC-004, which may represent a next-generation, non-opioid treatment for patients suffering from chronic pain.

CPHI Americas

STARJEMZA Becomes Bio-Thera’s Third FDA-Approved Product

STARJEMZA is approved as a biosimilar referencing Stelara (ustekinumab) Injection.

CPHI Americas

SGS Gains Canadian ISO 17025 Accreditation for E&L Testing

This service in Canada will increase the company’s E&L testing capacity for North American clients.

CPHI Americas

Fresenius Kabi Introduces Epinephrine Injection 30 mg per 30 mL Multi-Dose Vials

New product expands company’s line of Epinephrine injectables.

CPHI Americas

Astoriom Expands Sample Stability Storage Services

Additional capacity provides greater storage availability to support R&D and regulatory studies.